The present disclosure discloses glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma. (Eg, delaying the onset or reducing the risk of development) and treating (eg, controlling progression) cancers including, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. To reduce, slow down, or slow down) novel compounds of Formula I and their pharmaceutically acceptable salts, solvates, solvate salts, and prodrugs. The compounds of the present disclosure are selective antagonists of EP4 receptors and are useful in the treatment of a variety of disorders that may be ameliorated by blockade of PGE2-mediated signaling. [Chemical 1] [Selection diagram] None本開示は、膠芽腫、骨癌、頭頚部癌、黒色腫、基底細胞癌、有棘細胞癌、腺癌、口腔癌、食道癌、胃癌、腸癌、結腸癌、膀胱癌、肝細胞癌、腎細胞癌、膵臓癌、卵巣癌、子宮頚癌、肺癌、乳癌、および前立腺癌を含む癌の予防（例えば、発症を遅らせるか、発達のリスクを低下させる）および処置（例えば、進行を制御するか、緩和するか、または遅くする）に有用な新規な式Ｉの化合物およびその薬学的に許容可能な塩、溶媒和物、溶媒和物の塩、およびプロドラッグに関連する。本開示の化合物はＥＰ４受容体の選択的なアンタゴニストであり、かつＰＧＥ２媒介シグナル伝達の遮断により改善され得る様々な疾患の処置に有用である。【化１】【選択図】なし
